Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Larsson

Showing results (11-20 of 180) with videos related to

Pageof 18
Sort By:
Chemotherapy|September 10, 2002
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patientsSara Ekelund, Ingrid Persson, Rolf Larsson, et al.
Experimental Cell Research|April 11, 2012
Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture systemHenning Karlsson, Mårten Fryknäs, Rolf Larsson, et al.
Cancer Science|January 6, 2011
Aminopeptidase N (CD13) as a target for cancer chemotherapyMalin Wickström, Rolf Larsson, Peter Nygren, et al.
Journal of Biomolecular Screening|January 9, 2007
Image-based screening for the identification of novel proteasome inhibitorsLinda Rickardson, Malin Wickström, Rolf Larsson, et al.
SLAS Technology|April 6, 2017
Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-AnalysisKristin Blom, Peter Nygren, Rolf Larsson, et al.
International Journal of Biomaterials|July 26, 2012
Advanced surface modifications for blood-contacting surfaces of medical devicesZhongjun J Wu, Narayana Garimella, Rolf Larsson, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2009
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published dataAnne von Heideman, Ake Berglund, Rolf Larsson, et al.
Cancer Research|August 3, 2002
Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1Henrik Lövborg, Jacek Wojciechowski, Rolf Larsson, et al.
Statistics in Medicine|November 26, 2020
Simulation model of disease incidence driven by diagnostic activityMarcus Westerberg, Rolf Larsson, Lars Holmberg, et al.
Cancer Letters|June 9, 2004
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemiaSynnöve Lindemalm, Jan Liliemark, Gunnar Juliusson, et al.
Pageof 18

Showing results (11-20 of 180) with videos related to

Sort By:
Pageof 18
Chemotherapy|September 10, 2002
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patientsSara Ekelund, Ingrid Persson, Rolf Larsson, et al.
Experimental Cell Research|April 11, 2012
Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture systemHenning Karlsson, Mårten Fryknäs, Rolf Larsson, et al.
Cancer Science|January 6, 2011
Aminopeptidase N (CD13) as a target for cancer chemotherapyMalin Wickström, Rolf Larsson, Peter Nygren, et al.
Journal of Biomolecular Screening|January 9, 2007
Image-based screening for the identification of novel proteasome inhibitorsLinda Rickardson, Malin Wickström, Rolf Larsson, et al.
SLAS Technology|April 6, 2017
Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-AnalysisKristin Blom, Peter Nygren, Rolf Larsson, et al.
International Journal of Biomaterials|July 26, 2012
Advanced surface modifications for blood-contacting surfaces of medical devicesZhongjun J Wu, Narayana Garimella, Rolf Larsson, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2009
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published dataAnne von Heideman, Ake Berglund, Rolf Larsson, et al.
Cancer Research|August 3, 2002
Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1Henrik Lövborg, Jacek Wojciechowski, Rolf Larsson, et al.
Statistics in Medicine|November 26, 2020
Simulation model of disease incidence driven by diagnostic activityMarcus Westerberg, Rolf Larsson, Lars Holmberg, et al.
Cancer Letters|June 9, 2004
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemiaSynnöve Lindemalm, Jan Liliemark, Gunnar Juliusson, et al.
Pageof 18